Treatment effects monitoring committees and early stopping in large clinical trials - PubMed (original) (raw)
Treatment effects monitoring committees and early stopping in large clinical trials
Antariksha Kiri et al. Clin Trials. 2004 Feb.
Abstract
Background: Treatment effects monitoring is a process carried out over the course of a trial to determine whether it should continue unaltered. The purpose of monitoring is to protect persons enrolled from harm, caused either by exposure to an ineffective or harmful treatment or failure to provide a better treatment. The aim of this paper is to characterize treatment effects monitoring committees (TEMCs) as extant in published trials and to examine the effect of their presence on the premature stopping of a trial.
Methods: Trials published in 1990-1995 in the Annals of Internal Medicine, Archives of Internal Medicine, British Medical Journal, Journal of the American Medical Association, Lancet, New England Journal of Medicine or Controlled Clinical Trials were identified via MEDLINE (4279 publications). Abstracts were screened to include only trials with parallel treatment designs and sample sizes of > or = 200, reducing the set to 661 papers. Those papers were then read, reducing the set to 562 after exclusion of papers not reporting trial results. The results that follow come from a review of these 562 published papers and from the responses to two questionnaires. The first was mailed to the corresponding author, and the second to the chair of the monitoring body or other contact as provided by the author in response to the first questionnaire.
Results: Less than half (48%) of the 562 trials had TEMCs. Factors having a positive univariate relationship with the presence of a TEMC include National Institutes of Health (NIH) sponsorship, larger sample size, multicentered, longer data collection and follow-up, and mortality as an outcome. Most of the early stops occurred in trials with TEMCs (66 out of 78). The odds ratios for early stopping for trials with TEMCs versus those without TEMCs was 4.4 (CI: 2.3-8.5).
Conclusions: The evidence suggests that early stopping is associated with the presence of a TEMC, but a substantial number of trial reports do not mention the presence of a TEMC even when one was used to stop a trial early.
Comment in
- Monitoring data on data monitoring.
Ellenberg SS. Ellenberg SS. Clin Trials. 2004 Feb;1(1):6-8. doi: 10.1191/1740774504cn001ed. Clin Trials. 2004. PMID: 16281457 No abstract available.
Similar articles
- Reporting on data monitoring committees in neonatal randomised controlled trials is inconsistent.
Perrem LM, Gosling S, Ravikumar I, Khashan AS, Miletin J, Ryan CA, Dempsey E. Perrem LM, et al. Acta Paediatr. 2017 Jan;106(1):30-33. doi: 10.1111/apa.13593. Epub 2016 Oct 25. Acta Paediatr. 2017. PMID: 27637413 - Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study.
Sydes MR, Altman DG, Babiker AB, Parmar MK, Spiegelhalter DJ; DAMOCLES Group. Sydes MR, et al. Clin Trials. 2004 Feb;1(1):48-59. doi: 10.1191/1740774504cn003oa. Clin Trials. 2004. PMID: 16281462 - Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Higashida RT, et al. Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17. Stroke. 2003. PMID: 12869717 - Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials.
Pocock SJ, Clayton TC, Stone GW. Pocock SJ, et al. J Am Coll Cardiol. 2015 Dec 29;66(25):2886-2898. doi: 10.1016/j.jacc.2015.10.051. J Am Coll Cardiol. 2015. PMID: 26718676 Review. - An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
Stegert M, Kasenda B, von Elm E, You JJ, Blümle A, Tomonaga Y, Saccilotto R, Amstutz A, Bengough T, Briel M; DISCO study group. Stegert M, et al. J Clin Epidemiol. 2016 Jan;69:152-60. doi: 10.1016/j.jclinepi.2015.05.023. Epub 2015 Jun 4. J Clin Epidemiol. 2016. PMID: 26361993 Review.
Cited by
- CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. Moher D, et al. BMJ. 2010 Mar 23;340:c869. doi: 10.1136/bmj.c869. BMJ. 2010. PMID: 20332511 Free PMC article. No abstract available. - A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials.
Fernandes RM, van der Lee JH, Offringa M. Fernandes RM, et al. BMC Pediatr. 2009 Dec 13;9:77. doi: 10.1186/1471-2431-9-77. BMC Pediatr. 2009. PMID: 20003383 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical